Akari Therapeutics (AKTX) Depreciation & Amortization (IS) (2016 - 2022)
Akari Therapeutics recorded quarterly Depreciation & Amortization (IS) of $942.0 in Q2 2022, down 6.36% quarter-over-quarter from $1006.0 in Q1 2022, and down 10.11% year-over-year from $1048.0 in Q2 2021.
Akari Therapeutics' Depreciation & Amortization (IS) history runs 7 years deep, the most recent figure standing at $942.0 for Q2 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Dep. & Amort. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 127,436.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 12.00 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 942.00 |
| Mar 31, 2022 | 1,006.00 |
| Sep 30, 2021 | 3.12 Bn |
| Jun 30, 2021 | 1,048.00 |
| Mar 31, 2021 | 1,034.00 |
| Sep 30, 2020 | 7.91 Bn |
| Jun 30, 2020 | -3.88 Bn |
| Mar 31, 2020 | 3.88 Bn |
| Sep 30, 2019 | 4,626.00 |
| Jun 30, 2019 | 4,700.00 |
| Mar 31, 2019 | 5,566.00 |
| Sep 30, 2018 | 9,508.00 |
| Jun 30, 2018 | 9,378.00 |
| Mar 31, 2018 | 9,344.00 |
| Sep 30, 2017 | 10,344.00 |
| Jun 30, 2017 | 11,714.00 |
| Mar 31, 2017 | 10,839.00 |
| Sep 30, 2016 | 9,677.00 |
| Jun 30, 2016 | 10,191.00 |
| Mar 31, 2016 | 8,594.00 |